Intellia Therapeutics reported further progress with two treatments that are now ensconced in Phase III of testing. Click ...

A joint investigation by the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, and state and ...

Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

Topline pivotal Phase 3 firmonertinib data. ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and ...

IND application submission on track for Q2 2025: MBX 4291, a GLP-1/GIP co-agonist prodrug, is being developed as a once-monthly treatment for obesity. The Company expects to submit an IND application ...